RACHEL HUMPHREY was named chief medical officer of CytomX. Humphrey previously served as a member of the company’s board of directors.
Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca, and also oversaw clinical development of Yervoy (ipilmumab) at Bristol-Myers Squibb and the development of Nexavar (sorafenib) at Bayer.
Humphrey recently held positions as vice president and head of immuno-oncology at Eli Lilly and at AstraZeneca, where she was responsible for building the immuno-oncology departments and supervising the strategies and designs for all the immuno-oncology agents in development.
She previously served as vice president of product development at Bristol-Myers Squibb, where she led all aspects of the clinical development of Yervoy through the submission of global biologics license applications and global launch.
At Bayer, Humphrey supervised the early and late stage clinical development of Nexavar for treatment of renal cell carcinoma. She began her career as an oncology fellow and staff physician at the NCI.
In connection with her appointment as chief medical officer, Humphrey will resign from the board of directors of CytomX.
